Significant improvement in specific bronchial challenge test after 6 months of immunotherapy with a standardized depigmented and polymerized Dermatophagoides pteronyssinus extract (Depigoid®)

Ferrer, A.; García-Sellés, J.; García-Ortega, P; Bartra, Joan; Gaig, P.; Gómez, María José; Fernández-Caldas, Enrique; Casanovas, Miguel

doi:10.1016/s0091-6749(02)81742-0

Cited by 14 publications

(18 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…32 In this study, we have confirmed that treating patients who are sensitized to Chenopodiacea with a modified S kali extract is efficacious in reducing symptoms and improving quality of life parameters in this patient population. This type of modified allergen extract has previously shown efficacy using D pteronyssinus, 19,33 a mixture of D pteronyssinus and D farinae, 34 O europaea, 35 a mixture of O europaea and Dactylis glomerata, 26 and P judaica. 36 The safety of this vaccine has also been the subject of several comparative, controlled studies, demonstrating an excellent safety profile.…”

Section: Discussionmentioning

confidence: 99%

Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule

Colás

Monzón

Venturini

et al. 2006

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule

Colás

Monzón

Venturini

et al. 2006

Journal of Allergy and Clinical Immunology

View full text Add to dashboard Cite

“…Thirteen patients experienced systemic reactions, all judged to be mild. Other studies have also demonstrated the effi cacy of treatment with depigmented polymerized extracts of mites [17], P. judaica [14], O. europaea [18] and P. pratense [16] and the absence of moderate or severe systemic reactions.…”

Section: Discussionmentioning

confidence: 99%

“…The safety and effi cacy of these modifi ed allergen extracts have been proven for house dust mites [17], Parietaria judaica [14], Olea europaea [18] and Phleum pratense [16], using chemically modifi ed doses exceeding 10 times the regular doses of non-modifi ed vaccines.…”

Section: Introductionmentioning

confidence: 99%

Comparative Study of Tolerance between Unmodified and High Doses of Chemically Modified Allergen Vaccines of <i>Dermatophagoides pteronyssinus</i>

Casanovas

Fernández-Caldas

Alamar³

et al. 2005

Int Arch Allergy Immunol

Self Cite

View full text Add to dashboard Cite

Background: The physiochemical modification of allergens to reduce allergenicity, while retaining immunogenicity, provides a chance for the administration of higher doses of immunotherapy, with a decreased risk of systemic reactions. Objective: To evaluate the safety of doses of depigmented glutaraldehyde-polymerized vaccine of Dermatophagoides pteronyssinus increasing those used in normal clinical conditions in comparison with regular doses of a non-modified vaccine. Materials and Methods: The study was double-blind, parallel and included two patient groups. Twenty-three patients were treated weekly during 9 visits for the build-up phase, followed by 2-weekly maintenance doses (a total of 11 injections per patient). Eleven patients (mean age 22 years) received immunotherapy with the standardized modified vaccine. The maximum dose used was the result of depigmenting and polymerizing 100 times the maximum dose used with the native extract. The maximum concentration used was 990 µg/ml of freeze-dried material. Twelve patients (mean age 24 years) received a standardized, unmodified allergenic extract. The maximum concentration used was 70 µg of freeze-dried material/ml, with a potency of 10 HEP_L/ml. The tolerance was evaluated recording all the side reactions related to immunotherapy and graded following the recommendations of the European Academy of Allergology and Clinical Immunology. Results: In both groups, all immediate local reactions were clinically not relevant. Patients treated with the native extract experienced 42 local immediate and 24 delayed reactions (1 of them had a diameter >10 cm), whereas patients treated with the modified extract experienced 30 local immediate and 21 delayed reactions (2 of them had a diameter >10 cm). Four systemic reactions in 2 patients, 1 immediate of grade 1 and 3 delayed of grade 2 were reported in the group treated with native extract and 1 delayed of grade 2 in the group treated with the modified preparation. Conclusions: The modified extract of D. pteronyssinus, used at concentrations which are 10 times higher than those regularly administered in clinical practice, demonstrated to be safe to treat D. pteronyssinus-sensitive patients. The major ity of the local reactions (immediate and delayed) were clinically not relevant (diameter <5 cm). No systemic reactions of grade 3 or 4 were noted.

show abstract

“…Some studies using mite allergen extracts have shown that the efficacy occurs after a few months of treatment [32][33][34], achieving a more rapid improvement when a cluster schedule is used [18]. Ferrer et al [32] demonstrated a significant difference in the PD 20 FEV 1 of native extract of D. pteronyssinus (P = 0.0029) in a group of patients after 6 months of treat- At the end of this study, 10 patients in the immunotherapy-treated group versus one in the control group needed more than twice the amount of allergen than at baseline to reach PD 20 FEV 1 (P = 0.03). Symptom and medication scores and visual scale improved after 3 and 6 months of treatment only in the active group.…”

Section: Introductionmentioning

confidence: 99%

Mite immunotherapy

Fernández-Caldas¹,

Iraola²,

Boquete³

et al. 2006

Curr Allergy Asthma Rep

Self Cite

View full text Add to dashboard Cite

Dermatophagoides pteronyssinus and D. farinae are the most common house dust mites and are among the most common sources of indoor allergens worldwide. These species are very common in humid regions, where most allergic individuals are sensitized to house dust mites. Specific immunotherapy with mite extracts has demonstrated clinical benefits in several double-blind, placebo-controlled trials that are included in recent reviews of subcutaneous immunotherapy, including pediatric and adult patients with rhinoconjunctivitis and or asthma. Most successful studies of mite immunotherapy have used native allergen extracts adsorbed onto aluminum hydroxide, or chemically modified mite-allergen extracts. Several studies have also shown efficacy using sublingual immunotherapy in pediatric and adult patients with asthma and/or rhinitis. Additionally, the efficacy of subcutaneous immunotherapy has been demonstrated in patients with atopic dermatitis, although more double-blind, placebo-controlled studies are needed. Based on several studies, it cannot be concluded that mite immunotherapy is more dangerous or safer than immunotherapy with grasses, epithelia, or animal epithelia. Because the delivery of high doses of allergen carries with it the risk for immunoglobulin E (IgE)-mediated events, several methods have been developed to reduce specific IgE binding to mite-allergen extracts. An important challenge for future mite immunotherapy modalities is the delivery of relatively high doses without a significant risk for severe reactions.

show abstract

Significant improvement in specific bronchial challenge test after 6 months of immunotherapy with a standardized depigmented and polymerized Dermatophagoides pteronyssinus extract (Depigoid®)

Cited by 14 publications

References 0 publications

Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule

Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule

Comparative Study of Tolerance between Unmodified and High Doses of Chemically Modified Allergen Vaccines of <i>Dermatophagoides pteronyssinus</i>

Mite immunotherapy

Contact Info

Product

Resources

About